Asklepion Pharmaceuticals, LLC

Linkedin
  • Home
  • Company
    • About Us
    • Leadership
    • Careers
  • News
  • Research & Pipeline
    • Clinical Trials
      • Acute Lung Injury Induced by CBP
        • Clinical Trial Sites
    • Pipeline
      • IV Citrulline
  • Contact Us
logo
  • WE ARE A
    PEDIATRIC, RARE
    DISEASE
    PHARMACEUTICAL
    DEVELOPMENT COMPANY
  • Our passions.
    Our focus.
    Our mission.
  • ASKLEPION PHARMACEUTICALS
    IS DEDICATED TO YOU.

Welcome to Asklepion Pharmaceuticals.


Asklepion is focused on the discovery, development, and commercialization of pharmaceutical products to help patients who have little to no therapeutic options, due to the rarity of their conditions.

Asklepion aims to provide treatment options for children with rare diseases.

About UsClinical Trials

Latest News


Asklepion Pharmaceuticals Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Program of Intravenous Citrulline

Asklepion Pharmaceuticals Presents Phase 1b/2a Clinical Trial Data for IV-Citrulline at the Pediatric Cardiac Intensive Care Society 13th Annual International Meeting

Asklepion Pharmaceuticals, LLC announces receipt of Orphan Drug Designation from U.S. FDA. January 9, 2017

FDA has granted orphan drug designation to L-citrulline for prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients. January 9, 2017

Industry Awards and Recognitions


March, 2016. Asklepion Pharmaceuticals, was awarded a 2016 Rare Impact Award by the National Organization for Rare Disorders (NORD).
January, 2016. Asklepion Pharmaceutical’s first product Cholbam® (cholic acid) is listed in the U.S. Food and Drug Administration’s Novel Drug Summary for 2015.

Company

About Us
Leadership
Careers
News

Research & Pipeline

Clinical Trials
Acute Lung Injury Induced by CPB
Clinical Trial Sites
Pipeline
IV Citrulline

Contact

Contact us
LinkedIn

Copyright © 2019 Asklepion Pharmaceuticals, LLC. All rights reserved.

Terms & Conditions | Privacy Policy

Back to Top